Related Experiment Video

Updated: Dec 21, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K

COVID-19 and coagulative axis: review of emerging aspects in a novel disease

Matilde Boccia1, Luigi Aronne2, Benito Celia3

  • 1Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples. bocciamatilde@gmail.com.

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|May 20, 2020
PubMed

Insights

COVID-19 often causes coagulopathy, with altered coagulation parameters in severe cases. Assessing thrombosis risk and using anticoagulants like low-molecular-weight heparin (LMWH) can improve patient management.

Area of Science:

  • Medical Research
  • Hematology
  • Infectious Diseases

Background:

  • COVID-19 is frequently associated with coagulopathy.
  • Disseminated intravascular coagulation (DIC) is observed in most fatal COVID-19 cases.
  • Altered coagulation parameters correlate with poor prognosis in COVID-19 patients.

Purpose of the Study:

  • To review the evidence linking COVID-19 to coagulation disorders.
  • To highlight the role of inflammation and hypoxia in COVID-19-related thrombosis.
  • To discuss the clinical management of thrombosis in COVID-19 patients.

Main Methods:

  • Literature review of recent evidence on COVID-19 and coagulopathy.
  • Analysis of established links between viral infections, inflammation, and coagulation.
  • Examination of hypoxia's role in thrombus formation.

Main Results:

  • COVID-19 commonly presents with coagulopathy and altered coagulation parameters.
  • Inflammation, viral infection, and hypoxia contribute to thrombosis in COVID-19.
  • Sepsis-induced coagulopathy (SIC) criteria and elevated D-dimer indicate a need for anticoagulation.

Conclusions:

  • Assessing thrombosis risk in COVID-19 patients is crucial for clinical management.
  • Anticoagulant therapy, particularly low-molecular-weight heparin (LMWH), should be tailored based on patient criteria.
  • Further research is needed to optimize therapeutic strategies for COVID-19-associated thromboembolism.

More Related Videos

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.3K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K

Related Concept Videos

Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.4K
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.1K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
287
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.8K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
187
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.4K